Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lilly Pairs Up with Daiichi Sankyo to Commercialize Migraine Med Galcanezumab in Japan
November 2, 2020
- Daiichi Sankyo to Buyback 60 Million of Own Shares, Canceling 180 Million Treasury Shares
November 2, 2020
- Astellas Completes US iota Buyout to Shore Up Development of Implantable Medical Devices
November 2, 2020
- Takeda Done with Majority of Non-Core Asset Divestitures with US$10 Billion Target Achieved: CEO
October 30, 2020
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Emerging from Repeated Price Cuts, Opdivo’s Japan Sales Could Top 100 Billion Yen in FY2020
October 30, 2020
- Ono’s Half-Year Operating Profit Up 25.1% on Double-Digit Drop in R&D, SGA Costs Amid COVID-19
October 30, 2020
- GSK Might Adjust Shipments for Cervarix as Surge in Demand Expected
October 29, 2020
- Sumitomo Dainippon’s Japan Sales Activities Hit by COVID-19, Virtual Calls Strengthened: President
October 29, 2020
- Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
October 29, 2020
- Santen Gets Asian Rights to Aerie’s Glaucoma Meds
October 29, 2020
- Enhertu Earns FDA’s Priority Tag for Gastric Cancer, Decision Due in Q1 2021
October 29, 2020
- AbbVie’s JAK Inhibitor Rinvoq Filed for Atopic Dermatitis in Japan
October 29, 2020
- Eisai Launches JV in China to Forge Health Service Platform for Elderly
October 29, 2020
- Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
- 1st Patient Enrolled in Global COVID-19 Study for Eritoran, Apremilast
October 28, 2020
- Opdivo Plus Cabometyx Filed for RCC in Japan: Ono/Takeda
October 28, 2020
- Opdivo-Yervoy Pair Filed for Malignant Pleural Mesothelioma in Japan
October 28, 2020
- Eisai Snaps Up Worldwide Rights for All of Cogstatethe’s Cognitive Function Tests
October 28, 2020
- Takeda Files Japan NDA for Short Bowel Syndrome Drug
October 28, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…